Association between unstable angina and CXCL17: a new potential biomarker

1 Introduction

Cardiovascular diseases are the leading causes of death worldwide. It is well known that the common and important pathological process of most cardiovascular diseases is atherosclerosis. Mechanistically, the rupture of atherosclerotic plaque leads to thrombosis which clogs the lumen and subsequently results in ischemia of the distal blood supply area, which is recognized as the main cause of acute cardiovascular and cerebrovascular events. However, the pathogenesis of atherosclerosis has not yet been fully elucidated.

Low-grade chronic inflammations are the key characteristics and potential pathogenic factors in cardiometabolic diseases, especially atherosclerosis [1]. The activated immune and non-immune cells produce a set of cytokines, including type I IFNs, pro-inflammatory cytokines, and chemokines, which interact with their corresponding receptors to orchestrate the next phase of immune and inflammatory responses. Thus, excessive activation of these signals are deleterious to the homeostasis of the affected cardiovascular system [2]. Recent studies have found that GPR35, the receptor for chemokine (C-X-C motif) ligand 17 (CXCL17), is closely related to cardiovascular diseases [3, 4]. CXCL17 which is abnormally expressed in primary colon cancer and breast cancer plays an important role in chemotactic monocytes, macrophages and mature or immature dendritic cells [5, 6], and even is involved in the angiogenesis for tumor development and regulation of the expression of vascular endothelial growth factor [5-7]. However, the function of CXCL17 in the development of cardiovascular diseases, especially in atherosclerosis, is unclear. Therefore, the aim of this study is to investigate the relationship between CXCL17 and atherosclerosis-related diseases.
2 Patients and Methods

2.1 Subjects

For our study we enrolled patients of the Department of Cardiology of Tongren Municipal People’s Hospital, from January 2017-October 2017. A total of 140 subjects were included in our study: 48 patients with UA, 51 patients with SA and 41 patients for CG. The primary inclusion criterion was clinical chest pain. All patients completed coronary angiography within three days of admission. After coronary angiography, the patients diagnosed as coronary heart disease (CHD) were divided into unstable and stable angina, while the normal coronary arteries were included in the control group. CHD was defined as coronary stenosis ≥50% and Gensini score was calculated according to the results of coronary angiography. Considering that stress and acute inflammatory response may affect the changes of chemokines, our study excluded patients with acute myocardial infarction, acute or chronic inflammatory diseases such as infectious disease, chronic congestive heart failure, neoplasms, autoimmune diseases and pregnant women. Percutaneous coronary intervention was performed in patients with ischemic symptoms and coronary stenosis ≥75%.

2.2 Ethics statement

This study was approved by the ethics committee of Tongren Municipal People’s Hospital and conducted according to the principles described in the Declaration of Helsinki. Written informed consent was obtained from all study participants.

2.3 Sample preparation

All subjects underwent 3 ml venous blood draw to test Troponin T (cTNT) and Brain natriuretic peptide (BNP) immediately at hospitalization. Another 3 ml venous blood sample used to test CXCL17 and biochemical indicators was collected in the morning after 8 hours of fasting. The samples were left at room temperature for 30 minutes to naturally solidify and successively centrifuged to extract the serum. The samples were then stored in -40 centigrade refrigerators and used for detecting the concentration of CXCL17 after three months.

2.4 Index assays

The concentration of CXCL17 was measured by ELISA kit (purchased from Bio-Swamp, NO:HM11279) and the procedure was performed according to the instructions. Kit detection range from 15pg/ml to 1200pg/ml, sensitivity: ≤3pg / ml. The indexes of blood lipid including total cholesterol, triglyceride, low density lipoprotein, high density lipoprotein and high sensitivity C-reactive protein (hs-CRP) were measured by an automatic biochemical analyzer.

2.5 Statistical Analysis

All statistical analyses were carried out with the SPSS 17.0 software and the data were presented as the mean ± SD. Categorical variables were presented as counts and percentages. Independent sample t-tests or ANOVA were performed to compare groups of continuous variables, and χ2 analysis was used to compare categorical data. Spearman correlation coefficients were calculated for the associations between the CXCL17 levels and the Gensini score or hs-CRP. Logistic regression was used to determine the relationship between CXCL17 and unstable angina after adjusting for confounding factors. All tests were two-sided, and significance was set at P<0.05.

3 Results

3.1 The variation of characteristics among CHD patients in different three groups

As shown in Table 1, the comparison among CHD patients with SA, UA and CG group showed statistically significant higher CXCL17 levels in the UA compared to the SA group (UA 461.11±85.42 vs SA 339.67±95.11, p<0.001). Interestingly, no significant difference was found between SA and CG (SA:339.67±95.11 vs CG:325.44±98.09, p=0.466). Troponin T (cTNT) and hs-PCR in the UA group was significantly higher than in the SA and CG. No differences in age, sex, BMI, EF, TIMI blood flow and the lipid parameters were found among the three groups, while the incidence of smoking, hypertension and diabetes were significantly higher in the UA group.
3.2 Correlation between CXCL17, Gensini score and hs-CRP

Hs-CRP is a well-known traditional risk factor for CHD [8, 9], while Gensini score is a common indicator of the severity of CHD [10]. Thus, we compared hs-CRP and Gensini score between UA and SA. The UA group had a significant higher level of hs-CRP (SA 1.98±0.70 vs UA 5.61±3.52, p<0.001) and Gensini score (SA 19.25±24.48 vs UA 35.26±29.48, P=0.004) as shown in Table 2. Subsequently, we compared whether CXCL17 was related to hs-CRP and Gensini score. According to Spearman’s correlation method, CXCL17 had a positive association with hs-CRP (Figure 1) (r=0.644, p<0.001), whereas no correlation was found with Gensini score (Figure 2) (r=0.109, p=0.282).

3.3 Association between CXCL17 and the cardiovascular risk factors in unstable angina

In order to test whether CXCL17 was an independent risk factor for UA, a logistic regression analysis was made.

Table 1: Comparison of the characteristics between patients with SA, UA and control group.

|                          | Control (n=41) | SA (n=51) | UA (n=48) | F/χ² | P (CT vs SA) | P (CT vs UA) | P (SA vs UA) |
|--------------------------|---------------|-----------|-----------|------|--------------|--------------|--------------|
| Age (years)              | 58.99±9.722   | 62.15±8.67| 59.72±12.41| 2.924      | 0.025        | 0.590        | 0.075        |
| Sex (M/F)                | 23/18         | 37/14     | 35/13     | 5.307      | 0.100        | 0.097        | 0.967        |
| BMI                      | 24.63±3.47    | 23.86±1.46| 24.79±2.36 | 1.953      | 0.144        | 0.763        | 0.066        |
| Smoking (cases)          | 18            | 27        | 32        | 6.692      | 0.389        | 0.031        | 0.164        |
| Hypertension (cases)     | 8             | 31        | 18        | 13.814     | <0.001       | 0.063        | 0.021        |
| Diabetes (cases)         | 1             | 11        | 9         | 7.655      | 0.007        | 0.015        | 0.727        |
| TC (mmol/L)              | 4.03±1.09     | 3.89±1.25 | 4.25±1.15 | 1.125      | 0.588        | 0.383        | 0.138        |
| HDL (mmol/L)             | 1.09±0.28     | 0.98±0.26 | 1.05±0.26 | 2.060      | 0.054        | 0.564        | 0.161        |
| TG (mmol/L)              | 1.71±1.20     | 1.95±1.26 | 1.93±1.12 | 0.544      | 0.343        | 0.383        | 0.950        |
| LDL (mmol/L)             | 2.63±0.80     | 2.55±1.02 | 2.73±0.85 | 0.483      | 0.653        | 0.627        | 0.328        |
| Hs-CRP (g/L)             | 2.48±1.52     | 1.98±0.70 | 5.61±3.52 | 36.349     | 0.292        | <0.001       | <0.001       |
| CXCL17 (pg/ml)           | 325.44±98.09  | 339.67±95.11 | 461.11±85.42 | 30.166     | 0.466        | <0.001       | <0.001       |
| EF (%)                   | 63.40±5.68    | 64.59±5.03 | 62.92±8.25 | 2.59       | 0.325        | 0.815        | 0.203        |
| TIMI (grade 3 /<grade 3) | 40/1          | 50/1      | 46/2      | 0.951      | 0.876        | 0.653        | 0.522        |
| CTNT (pg/ml)             | 24.47±41.46   | 22.29±49.80 | 898.34±1633.08 | 34.97      | 0.992        | <0.001       | <0.001       |

Treatment

|                           |               |           |           |      |              |              |              |
|---------------------------|---------------|-----------|-----------|------|--------------|--------------|--------------|
| Statin use (%)            | 6             | 26        | 45        | 44.437 | <0.001       | <0.001       | <0.001       |
| Aspirin use (%)           | 7             | 29        | 47        | 45.941 | <0.001       | <0.001       | <0.001       |
| Antihypertension therapy (%)| 8           | 16        | 40        | 34.279 | 0.237        | <0.001       | <0.001       |

UA: unstable angina; SA: stable angina; BMI: body mass index; TC: total cholesterol; HDL: High-Density Lipoprotein; TG: Triglyceride; LDL: Low-Density Lipoprotein; hs-CRP: high sensitivity C-reactive protein; cTNT: Troponin T; TIMI: thrombolysis in myocardial infarction; The data shows as mean±SD.
using different models (Model 1 and 2) as shown in Table 3. Adjustments for sex, age, body mass index, smoking, hypertension and diabetes were determined. After correction of the above related risk factors, the statistical analysis showed that CXCL17 was an independent risk factor for UA.

4 Discussion

Unlike acute myocardial infarction, there is no effective biomarker for unstable angina at present. Recent studies have found that many kinds of chemokines might be served as markers for unstable angina pectoris [11, 12]. For example, CCL2, CXCL8, CXCL9, CXCL10 and CCL7 are significantly up-regulated in patients with CHD [13, 14]. They are related to the severity of atherosclerosis independent of traditional cardiovascular risk factors [14]. CX3CR1, (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are closely related to refractory unstable angina and can be used as a specific marker [11, 15], while CX3CL1 is used as a marker of response to statin therapy [16]. However, little is known about the biological function of CXCL17 in atherosclerosis which is one of the chemokine of CXC family. The previous studies have demonstrated that CXCL17 is abnormally expressed in multiple target tissues of oncology patients [17, 18]. Meanwhile, CXCL17 acts as a chemo-attractant for monocytes and macrophages, which suggested that it could play an important role in the angiogenesis of tumor development [6].

Table 2: Comparison of the serum hs-CRP and Gensini score between stable angina and unstable angina groups.

|          | SA         | UA         | t       | P         |
|----------|------------|------------|---------|-----------|
| Gensini score | 19.25±24.48 | 35.26±29.48 | -2.929  | 0.004     |
| hs-CRP   | 1.98±0.70  | 5.61±3.52  | -7.011  | <0.001    |

UA: unstable angina; SA: stable angina; hs-CRP: high sensitivity C-reactive protein; The data shows as mean±SD.

Table 3: Logistic regression analyses of association between serum CXCL17 levels and unstable angina.

| CXCL17 | β     | S.E.   | Wald | P      | Exp(B)  | 95% C.I for Exp(B) |
|--------|-------|--------|------|--------|---------|--------------------|
|        |       |        |      |        | Lower  | Upper  |
| Model1 | 0.018 | 0.004  | 22.375 | <0.001 | 1.018  | 1.011  | 1.026  |
| Model2 | 0.017 | 0.004  | 17.666 | <0.001 | 1.017  | 1.009  | 1.025  |

Model 1: Unadjusted.
Model 2: Adjusted for sex, age, BMI, smoking, hypertension, diabetes.
CXCL17 expression could be induced in macrophages [19], especially in lung macrophages [20], and tightly co-regulated with vascular endothelial growth factor expression [6]. Although CXCL17 plays an important role in angiogenesis of tumors, it also has an anti-inflammatory effect in tissue repair [7]. A recent study exhibits that GPCR35 acted as the receptor of CXCL17 and is closely related to cardiovascular disease [3, 4]. In our study we showed that the serum levels of CXCL17 were an independent risk factor for UA, while there were no significant differences between patients with SA and the CG. The collected evidences suggested that CXCL17 could be used as a stable marker of UA, but not as a diagnostic tool for CHD.

Clinical studies have shown that the occurrence of cardiovascular events mainly depend on the stability of plaque [21], which is correlated to the severity of the inflammatory reactions [22]. Gensini score is commonly used to evaluate the severity of coronary lesions [10] without taking in consideration the stability of the plaque. In our study, Gensini score was significantly increased in patients with UA, but no correlation was found between the latter and CXCL17. This result indicated that CXCL17 had a possible role in the stability of the plaque and not into the degree of atherosclerosis.

Hs-CRP is an acute phase reactive protein, which is a classic inflammatory marker in AS [8, 9], especially in patients with acute coronary syndrome (ACS) [23]. Many acute phase proteins were found significantly increased in ACS patients, such as haptoglobin, alpha-1-antitrypsin, ceruloplasmin, alpha-1 glycoprotein. Their elevation is significantly correlated with CRP concentration, and appear to be closely related to the severity of coronary atherosclerosis and to myocardial damage [24]. CRP is showed to be significantly correlated to creatin kinase, lactate dehydrogenase, troponin I and with the incidence of major adverse cardiac events in ACS patients [25]. CRP levels are strongly related to myocardial damage more than to pre-existing inflammation [25]. High sensitivity C-reactive protein is used as a marker of unstable angina pectoris and acts as a prognostic factor for CHD [26, 27]. In our study, CXCL17 was positively correlated with the levels of hs-CRP. CXCL17 and hs-CRP were significantly higher in UA patients rather than in the SA group; this result can be explained by the increased inflammatory activity found in the unstable plaques [23, 28, 29]. CXCL17 levels were associated with inflammatory activity and with the instability of atherosclerotic plaques.

In the UA group, drugs (including statins, aspirin and anti-hypertension) were universally used compared to the other two groups, which could have some influence on inflammation. Nevertheless, the CXCL17 expression in UA group was still significantly up-regulated. Finally, considering that acute stress may have an effect on chemokines, we excluded from the study patients with acute myocardial infarction.

5 Conclusions

At present, little is known about the biological properties of CXCL17, which is mainly focused on tumors. Therefore, further research on the function of CXCL17 needs to be revealed. In our study, CXCL17 was found to be an independent risk factor for unstable angina. The serum levels of CXCL17 were significantly up-regulated in patients with unstable angina, while no significant differences were found between stable angina and the control group. Moreover, CXCL17 was statistically correlated with hs-CRP and was associated to inflammatory activity, as well as the instability of atherosclerotic plaques. Those results suggested that CXCL17 elevation may act as a potential biomarker to distinguish stable from unstable angina pectoris after exclusion of acute myocardial infarction.

Author contribution: Fu-han Gong took charge of designing the study and the main writer of the paper. Xiao-qiang Xiao and Xue-ping Zhang collected the patient information. Xue-sheng Wang and Zhen-lin Shu collected the participant samples.

Financial support: This work was supported by grants from the Tongren Municipal People’s Hospital Doctoral Fund and Surface projects of Tongren science and technology program (2017-47-2).

Conflicts of interest: The authors declare no conflict of interest.

Reference

[1] Zhang Y., Li H. Reprogramming Interferon Regulatory Factor Signaling in Cardiometabolic Diseases, Physiology (Bethesda), 2017, 32, 210-223
[2] Zhang Y., Zhang X. J., Wang P. X., Zhang P., Li H. Reprogramming Innate Immune Signaling in Cardiometabolic Disease, Hypertension, 2017, 69, 747-760
[3] Divorty N., Mackenzie A. E., Nicklin S. A., Milligan G. G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease, Front Pharmacol, 2015, 6, 41

[4] Maravillas-Montero J. L., Burkhardt A. M., Hevezi P. A., Carnevale C. D., Smit M. J., Zlotnik A. Cutting edge: GPR35/CXCR8 is the receptor of the mucosal chemokine CXCL17, J Immunol, 2015, 2019, 29-33

[5] Weinstein E. J., Head R., Griggs D. W., Sun D., Evans R. J., Swearingen M. L., et al. VCC-1, a novel chemokine, promotes tumor growth, Biochem Biophys Res Commun, 2006, 350, 74-81

[6] Ohlsson L., Hammarstrom M. L., Lindmark G., Hammarstrom S., Sitoony B. Ectopic expression of the chemokine CXCL17 in colon cancer cells, Br J Cancer, 2016, 114, 697-703

[7] Lee W. Y., Wang C. J., Lin T. Y., Hsiao C. L., Luo C. W. CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor, Am J Physiol Endocrinol Metab, 2013, 304, E32-40

[8] Hernandez-Diaz Y., Tovilla-Zarate C. A., Juarez-Rojop I., Banos-Gonzalez M. A., Torres-Hernandez M. E., Lopez-Narvaez M. L., et al. The role of gene variants in the inflammatory markers CRP and TNF-alpha in cardiovascular heart disease: systematic review and meta-analysis, Int J Clin Exp Med, 2015, 8, 11958-11984

[9] Chen L., Sun M., Liu H., Ma L., Wang T., Li P., et al. Association of plasma apolipoprotein CIII, high sensitivity C-reactive protein and tumor necrosis factor-alpha contributes to the clinical features of coronary heart disease in Li and Han ethnic groups in China, Lipids Health Dis, 2018, 17, 176

[10] Neeland I. J., Patel R. S., Estehardi P., Dhawan S., McDaniel M. C., Rab S. T., et al. Coronary angiographic scoring systems: an evaluation of their equivalence and validity, Am Heart J, 2012, 164, 547-552 e541

[11] Ikejima H., Imanishi T., Tsujioka H., Kashiwagi M., Kuroi A., Tanimoto T., et al. Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris, Circ J, 2010, 74, 337-345

[12] Li R. J., Yang M., Li J. F., Xue L., Chen Y. G., Chen W. Q. Circulating CD36 and fractalkine levels are associated with vulnerable plaque progression in patients with unstable angina pectoris, Clin Exp Pharmacol Physiol, 2014, 41, 863-869

[13] de Oliveira R. T., Mamoni R. L., Souza J. R., Fernandes J. L., Rios F. J., Gidlund M., et al. Differential expression of cytokines, chemokines and chemokine receptors in patients with coronary artery disease, Int J Cardiol, 2009, 136, 17-26

[14] Ye Y., Yang X., Zhao X., Chen L., Xie H., Zeng Y., et al. Serum chemokine CCL17/Thymus activation and regulated chemokine is correlated with coronary artery diseases, Atherosclerosis, 2015, 238, 365-369

[15] Kraaijeveld A. O., de Jager S. C., de Jager W. J., Prakken B. J., McColl S. R., Hapsels I., et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms, Circulation, 2007, 116, 1931-1941

[16] Damas J. K., Boulier A., Waehre T., Smith C., Sandberg W. J., Green S., et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy, Arterioscler Thromb Vasc Biol, 2005, 25, 2567-2572

[17] Li L., Yan J., Xu C., Zhen Z. J., Chen H. W., et al. CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma, PLoS One, 2014, 9, e110064

[18] Koringa P. G., Jakhwsa S. J., Bhatt V. D., Meshram C. P., Patel A. K., Fefar D. T., et al. Comprehensive transcriptome profiling of squamous cell carcinoma of horn in Bos indicus, Vet Comp Oncol, 2016, 14, 122-136

[19] Tucureanu M. M., Butoi E., Gan A. M., Stan D., Constantinescu C. A., Calin M., et al. Amendment of the cytokine profile in macrophages subsequent to their interaction with smooth muscle cells: Differential modulation by fractalkine and resistin, Cytokine, 2016, 83, 250-261

[20] Burkhardt A. M., Maravillas-Montero J. L., Carnevale C. D., Vilches-Cisneros N., Flores J. P., Hevezi P. A., et al. CXCL17 is a major chemotactic factor for lung macrophages, J Immunol, 2014, 193, 1668-1674

[21] Niccoli G., Liuzzo G., Montone R. A., Crea F. Advances in mechanisms, imaging and management of the unstable plaque, Atherosclerosis, 2014, 233, 467-477

[22] Zhang Y., Tan S., Xu J., Wang T. Hydrogen Therapy in Cardiovascular and Metabolic Diseases: from Bench to Bedside, Cell Physiol Biochem, 2018, 47, 1-10

[23] Alber H. F., Suessensbacher A., Weidinger F. [The role of inflammation in the pathophysiology of acute coronary syndromes], Wien Klin Wochenschr, 2005, 117, 445-455

[24] Brunetti N. D., Correale M., Pellegrino P. L., Cuculo A., Biase M. D. Acute phase proteins in patients with acute coronary syndrome: Correlations with diagnosis, clinical features, and angiographic findings, Eur J Intern Med, 2007, 18, 109-117

[25] Brunetti N. D., Troccoli R., Correale M., Pellegrino P. L., Di Biase M. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings, Int J Cardiol, 2006, 109, 248-256

[26] Seo W. W., Kim H. L., Kim Y. J., Yoon Y. E., Lee S. P., Kim H. K., et al. Incremental prognostic value of high-sensitive C-reactive protein in patients undergoing coronary computed tomography angiography, J Cardiol, 2016, 68, 222-228

[27] Seyedian S. M., Ahmadi F., Dadagh R., Davoodzadeh H. Relationship between high-sensitivity C-reactive protein serum levels and the severity of coronary artery stenosis in patients with coronary artery disease, ARYA Atheroscler, 2016, 12, 231-237

[28] Zakynthinos E., Pappa N. Inflammatory biomarkers in coronary artery disease, J Cardiol, 2009, 53, 317-333

[29] Gong F. H., Cheng W. L., Wang H., Gao M., Qin J. J., Zhang Y., et al. Reduced atherosclerosis lesion size, inflammatory response in miR-150 knockout mice via macrophage effects, J Lipid Res, 2018, 59, 658-669